{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:09:57Z","timestamp":1780571397943,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002002","name":"CRF","doi-asserted-by":"publisher","award":["C4024-22GF"],"award-info":[{"award-number":["C4024-22GF"]}],"id":[{"id":"10.13039\/100002002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong University Grants Committee"},{"name":"Research Grant Council General Research Grant Reference","award":["471613"],"award-info":[{"award-number":["471613"]}]},{"name":"Kingboard Precision Oncology Program and the Charlie Lee Charitable Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We investigated the feasibility of adding neoadjuvant FOLFOXIRI to chemoradiotherapy (CRT) in Chinese patients with high-risk, locally advanced rectal adenocarcinoma (LARC) and examined the prognostic significance of IGF2 and L1CAM expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients had non-metastatic, T3\/T4 disease with or without nodal involvement, threatened circumferential resection margin (CRM) and\/or sphincter involvement, received 4 cycles of a modified FOLFOXIRI regimen, followed by CRT, surgery, then adjuvant chemotherapy. Co-primary endpoints were objective response rate (ORR) and pathologic complete response rate (pCR). Secondary endpoints included overall survival (OS), relapse-free survival (RFS) and safety. Archival biopsies were analyzed for IGF2 and L1CAM expression using immunostaining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty patients were enrolled with median age of 60 years and median follow up of 72.7\u2009months. The ORR of FOLFOXIRI and CRT was 30.8% and 64.1%, respectively in 39 patients evaluated, 71.8% of them exhibiting TNM downstaging. For the entire cohort, the pCR rate was 20.5% and CRM was negative in 30 patients. The 3-year and 5-year OS were 79.5% and 59.5%, respectively. The 3-year RFS was 72.4%. Grade 3-4 toxicities to FOLFOXIRI were diarrhea (13%), neutropenia (8%), and vomiting (5%). Grade 3-4 toxicities to CRT were diarrhea (3%), rectal hemorrhage (3%), and sexual dysfunction (3%). High IGF2 expression was negatively correlated with disease-free survival (P\u2009=\u2009.0176) but not OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant modified FOLFOXIRI followed by concurrent capecitabine-RT and surgery was effective with manageable toxicities in Chinese patients with high risk LARC. Exploratory analyses showed that IGF2 expression may be a negative prognostic factor in LARC. (NCT01941641)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag162","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:41:48Z","timestamp":1777030908000},"source":"Crossref","is-referenced-by-count":0,"title":["Multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent chemoradiotherapy in Chinese patients with high-risk rectal cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-9595","authenticated-orcid":false,"given":"Rashid N","family":"Lui","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]},{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5850-2247","authenticated-orcid":false,"given":"Simon","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-2119","authenticated-orcid":false,"given":"Dennis C K","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0251-0253","authenticated-orcid":false,"given":"Leung","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C M","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4488-8609","authenticated-orcid":false,"given":"Esther H Y","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Hung","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-3212","authenticated-orcid":false,"given":"Frankie K F","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-6287","authenticated-orcid":false,"given":"Eric C H","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8989-1293","authenticated-orcid":false,"given":"Connie W C","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy C M","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6619-632X","authenticated-orcid":false,"given":"Joyce","family":"Suen","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Ming","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7358-5439","authenticated-orcid":false,"given":"Kaori","family":"Futaba","sequence":"additional","affiliation":[{"name":"Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9246-9011","authenticated-orcid":false,"given":"Sophie Sok Fei","family":"Hon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S M","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-1102","authenticated-orcid":false,"given":"Brigette Buig Yue","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong , Hong Kong SAR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026060406350945900_oyag162-B1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clcc.2022.07.005","article-title":"Outcomes of locally advanced rectal cancer patients treated with total neoadjuvant treatment: a meta-analysis of randomized controlled trials","volume":"21","author":"Gabbani","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"2026060406350945900_oyag162-B2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"key":"2026060406350945900_oyag162-B3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer","volume":"11","author":"Audisio","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026060406350945900_oyag162-B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.clcc.2021.12.004","article-title":"Total neoadjuvant therapy for high risk rectal cancer in Western and Asian populations - current evidence and clinical applications","volume":"21","author":"Johnson","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"2026060406350945900_oyag162-B5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.12809\/hkmj154788","article-title":"Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital","volume":"22","author":"Yeung","year":"2016","journal-title":"Hong Kong Med J"},{"key":"2026060406350945900_oyag162-B6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026060406350945900_oyag162-B7","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","article-title":"Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer","volume":"28","author":"Chatila","year":"2022","journal-title":"Nat Med"},{"key":"2026060406350945900_oyag162-B8","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.19.00308","article-title":"Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12","volume":"37","author":"Fokas","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026060406350945900_oyag162-B9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026060406350945900_oyag162-B10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060406350945900_oyag162-B11","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.18.02309","article-title":"Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial","volume":"37","author":"Deng","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026060406350945900_oyag162-B12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026060406350945900_oyag162-B13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1186\/s12885-024-12529-7","article-title":"Alliance A022104\/NRG-GI010: the Janus Rectal Cancer trial: a randomized phase II\/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer","volume":"24","author":"Alvarez","year":"2024","journal-title":"BMC Cancer"},{"key":"2026060406350945900_oyag162-B14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060406350945900_oyag162-B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2024.42.3_suppl.39","article-title":"Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): real-world experience from a tertiary Asian cancer center","volume":"42","author":"Wang","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"2026060406350945900_oyag162-B16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s12885-023-11103-x","article-title":"Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"2026060406350945900_oyag162-B17","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"2026060406350945900_oyag162-B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3857\/roj.2023.00038","article-title":"A practical review of watch-and-wait approach in rectal cancer","volume":"41","author":"Byun","year":"2023","journal-title":"Radiat Oncol J"},{"key":"2026060406350945900_oyag162-B19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41416-020-01084-0","article-title":"Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier","volume":"123","author":"Zhou","year":"2020","journal-title":"Brit J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag162\/68182077\/oyag162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag162\/68182077\/oyag162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag162\/68182077\/oyag162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:35:15Z","timestamp":1780569315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag162\/8664401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag162","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"oyag162"}}